Dynamics of Ischemia/Reperfusion Injury Markers During Normothermic Liver Machine Perfusion

Aránzazu Caballero-Marcos1,2, Luis Rodríguez-Bachiller3, Alberto Baroja-Mazo4

  • 1Hepatology and Liver Transplantation Unit, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain.

Transplantation Direct
|November 18, 2024
PubMed
Abstract

Insights

This study found that lactate levels in liver perfusate correlate with ischemia/reperfusion injury (IRI) mechanisms during normothermic machine perfusion (NMP). Accumulating IRI biomarkers during NMP may limit its benefits for liver viability assessment.

Area of Science:

  • Transplantation
  • Organ Preservation
  • Biomarker Discovery

Background:

  • Normothermic machine perfusion (NMP) is crucial for assessing liver viability, but a complete mechanistic understanding is needed.
  • While inflammation markers in NMP are studied, other ischemia/reperfusion injury (IRI) mechanisms require evaluation.
  • Identifying reliable biomarkers is essential to optimize NMP protocols and improve organ outcomes.

Purpose of the Study:

  • To comprehensively assess IRI mechanisms during NMP in human donor livers.
  • To identify and quantify specific biomarkers in perfusate that indicate liver injury.
  • To explore correlations between perfusate biomarkers and underlying pathological processes.

Main Methods:

  • Eight human donor livers were preserved using NMP.
  • Perfusate samples were collected throughout the NMP period.
  • Concentrations of various IRI-related biomarkers were measured.

Main Results:

  • Levels of adhesion molecules (ICAM-1, P-selectin, VCAM-1), MMP-13, PLA2G7, and syndecan-1 increased during NMP.
  • Perfusate lactate showed significant correlations with CXCL10, ICAM-1, and uPA.
  • Lactate levels in perfusate reflect key biological processes occurring during NMP.

Conclusions:

  • Perfusate lactate is a potential indicator of underlying biological mechanisms in NMP.
  • The accumulation of IRI biomarkers during NMP may pose limitations to its efficacy.
  • Further research is needed to validate these biomarkers for liver viability assessment.